SELANK [10mg]

Preclinical research has characterized SELANK primarily as an anxiolytic agent with a mechanism distinct from classical benzodiazepines. Work from Voronina, Semenova, and colleagues at the Institute of Pharmacology (Russian Academy of Medical Sciences) examined its effects on GABA-A receptor modulation, hippocampal serotonin metabolism, and BDNF expression levels in rodent models including elevated plus maze and fear-potentiated startle paradigms. A separate immunological line of research from Uchakina and Bubalo characterized SELANK's influence on circulating IL-6 and IFN-γ levels in peripheral immune cells. All findings referenced here derive from preclinical models and have not been validated in controlled human clinical trials.